You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Moodys
Dow
Boehringer Ingelheim

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for ITI-007

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ITI-007?

ITI-007 is an investigational drug.

There have been 25 clinical trials for ITI-007. The most recent clinical trial was a Phase 3 trial, which was initiated on September 21st 2020.

The most common disease conditions in clinical trials are Hemophilia A, Schizophrenia, and Depressive Disorder. The leading clinical trial sponsors are Intra-Cellular Therapies, Inc., Grifols Biologicals Inc., and CSL Behring.

There are twenty-nine US patents protecting this investigational drug and two hundred and five international patents.

Recent Clinical Trials for ITI-007
TitleSponsorPhase
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or SkinShattuck Labs, Inc.Phase 1
Preventing Inhibitor Recurrence IndefinitelyGrifols Biologicals, LLCPhase 4
Preventing Inhibitor Recurrence IndefinitelyChildren's Hospital Los AngelesPhase 4

See all ITI-007 clinical trials

Clinical Trial Summary for ITI-007

Top disease conditions for ITI-007
Top clinical trial sponsors for ITI-007

See all ITI-007 clinical trials

US Patents for ITI-007

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ITI-007   Start Trial Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
ITI-007   Start Trial Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
ITI-007   Start Trial Compounds and methods of use to treat schizophrenia INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
ITI-007   Start Trial Preparation of certain substituted [((6bR,10aS)-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,- 2,3-de]quinoxalines and pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
ITI-007   Start Trial Methods INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
ITI-007   Start Trial Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-p- yrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ITI-007

Drugname Country Document Number Estimated Expiration Related US Patent
ITI-007 European Patent Office EP2968320 2033-03-15   Start Trial
ITI-007 Hong Kong HK1220615 2033-03-15   Start Trial
ITI-007 World Intellectual Property Organization (WIPO) WO2014145192 2033-03-15   Start Trial
ITI-007 Australia AU2015240521 2034-04-04   Start Trial
ITI-007 Canada CA2944512 2034-04-04   Start Trial
ITI-007 China CN106535898 2034-04-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.